Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem.